Edition:
United States

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

23.44USD
25 May 2018
Change (% chg)

$-0.20 (-0.85%)
Prev Close
$23.64
Open
$23.53
Day's High
$23.98
Day's Low
$23.18
Volume
22,195
Avg. Vol
82,643
52-wk High
$37.00
52-wk Low
$3.13

Latest Key Developments (Source: Significant Developments)

Catalyst Biosciences Provides Corporate Update
Thursday, 1 Mar 2018 08:30am EST 

March 1 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.CATALYST BIOSCIENCES - ‍CASH BALANCE OF OVER $135 MILLION AFTER FEB FOLLOW-ON FINANCING ALLOWS FOR INDEPENDENT DEVELOPMENT OF LEAD PROGRAMS​.CATALYST BIOSCIENCES INC - ‍COMPANY HAS NO OUTSTANDING NOTES OR DEBT​.CATALYST BIOSCIENCES INC - ‍INTEREST AND OTHER INCOME FOR QUARTER WAS $0.1 MILLION, VERSUS $1.5 MILLION FOR PRIOR YEAR PERIOD​.  Full Article

Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D
Monday, 26 Feb 2018 08:00am EST 

Feb 26 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES MANUFACTURING AGREEMENT WITH AGC BIOLOGICS FOR SUBCUTANEOUS FACTOR IX PRODUCT CB 2679D.CATALYST BIOSCIENCES INC - PLAN TO INITIATE A PHASE 2B STUDY OF CB 2679D IN INDIVIDUALS WITH SEVERE HEMOPHILIA B IN Q3 OF 2018.  Full Article

Catalyst Biosciences Says Public Offering Of 2.94 Mln Common Shares Priced At $34/Share
Tuesday, 13 Feb 2018 08:45am EST 

Feb 13 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.94 MILLION COMMON SHARES PRICED AT $34.00PER SHARE.  Full Article

Catalyst Biosciences Announces Proposed Public Offering Of Common Stock
Monday, 12 Feb 2018 04:33pm EST 

Feb 12 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES - ‍ANTICIPATES USING OFFERING PROCEEDS FOR PURPOSES INCLUDING CLINICAL & MANUFACTURING ACTIVITIES FOR CB 2679D, MARZEPTACOG ALFA​.  Full Article

RTW Investments Reports A 5.71 Percent Passive Stake In Catalyst Biosciences
Monday, 5 Feb 2018 09:32am EST 

Feb 5 (Reuters) - Catalyst Biosciences Inc ::RTW INVESTMENTS, LP REPORTS A 5.71 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF JAN 26, 2018 .  Full Article

Catalyst Biosciences Files For Mixed Shelf Of Up To $150 Mln
Monday, 22 Jan 2018 05:17pm EST 

Jan 22 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING.  Full Article

Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences
Wednesday, 27 Dec 2017 01:36pm EST 

Dec 28 (Reuters) - Catalyst Biosciences Inc ::NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING.  Full Article

Catalyst Biosciences Announces Pricing Of Public Offering Of Common Stock
Wednesday, 20 Dec 2017 09:11am EST 

Dec 20 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES INC - ‍PRICING OF UNDERWRITTEN PUBLIC OFFERING OF 1.1 MILLION SHARES OF COMMON STOCK, OFFERED AT A PRICE OF $9.50 PER SHARE TO PUBLIC​.  Full Article

Catalyst Biosciences Announces Proposed Public Offering Of Common Stock
Tuesday, 19 Dec 2017 04:51pm EST 

Dec 19 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.CATALYST BIOSCIENCES INC - ANTICIPATES USING PROCEEDS FROM OFFERING FOR CLINICAL TRIALS, RESEARCH AND DEVELOPMENT ACTIVITIES, CAPEX.  Full Article

Catalyst Biosciences Appoints Edward Williams To Its Board
Thursday, 14 Dec 2017 08:30am EST 

Dec 14 (Reuters) - Catalyst Biosciences Inc ::CATALYST BIOSCIENCES ANNOUNCES APPOINTMENT OF EDWARD WILLIAMS TO ITS BOARD OF DIRECTORS.CATALYST BIOSCIENCES INC - BARRY SELICK, WHO HAS BEEN CHAIRMAN SINCE 2006, WILL STEP DOWN FROM BOARD EFFECTIVE FEB. 15, 2018.CATALYST BIOSCIENCES INC - ‍CURRENT BOARD MEMBER AUGUSTINE LAWLOR WILL REPLACE SELICK AS CHAIRMAN​.  Full Article

BRIEF-Catalyst Biosciences Reports Q1 Loss Per Share $0.56

* CATALYST BIOSCIENCES REPORTS FIRST QUARTER OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE